| scholarly article | Q13442814 |
| P2093 | author name string | Robert T Jensen | |
| Tetsuhide Ito | |||
| P2860 | cites work | Cancer risks from diagnostic radiology | Q22241582 |
| Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response | Q24301482 | ||
| ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes | Q24603675 | ||
| Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study | Q24617800 | ||
| Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies | Q24647838 | ||
| Management of pancreatic neuroendocrine tumors in patients with MEN 1 | Q27000026 | ||
| High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours | Q28260008 | ||
| Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) | Q28296266 | ||
| Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers | Q30319804 | ||
| Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas | Q31030383 | ||
| Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features | Q33258694 | ||
| Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 | ||
| ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors | Q34248466 | ||
| Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). | Q34283436 | ||
| Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium | Q34299991 | ||
| Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients | Q34744922 | ||
| NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas | Q35001777 | ||
| Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. | Q35640833 | ||
| Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome | Q68084123 | ||
| Insulinomas: localization with selective intraarterial injection of calcium | Q68175876 | ||
| Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study | Q68582798 | ||
| Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment | Q68914822 | ||
| Gastrinomas: comparison of MR imaging with CT, angiography, and US | Q69501262 | ||
| Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome | Q69860113 | ||
| Cushing's syndrome in patients with the Zollinger-Ellison syndrome | Q69882501 | ||
| Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study | Q71112902 | ||
| Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1 | Q71568271 | ||
| Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison | Q71591262 | ||
| Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study | Q72281843 | ||
| Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling | Q72388051 | ||
| Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas | Q72868839 | ||
| Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas | Q73009492 | ||
| Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1 | Q73141672 | ||
| Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas | Q73292253 | ||
| Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas | Q74029012 | ||
| [Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Experience of 54 cases] | Q74315122 | ||
| Thymic carcinoids in multiple endocrine neoplasia type 1 | Q74791955 | ||
| Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1 | Q74817189 | ||
| Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias | Q79775342 | ||
| Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging | Q80131055 | ||
| WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors | Q80146356 | ||
| Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1 | Q80938862 | ||
| Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series | Q81406313 | ||
| Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1 | Q82455992 | ||
| Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE | Q83300176 | ||
| Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1 | Q84629509 | ||
| Effective perioperative management of multiple endocrine neoplasia type 1-associated insulinomas | Q85486744 | ||
| Better Survival But Changing Causes of Death in Patients With Multiple Endocrine Neoplasia Type 1 | Q85937839 | ||
| Imaging of neuroendocrine tumors | Q86353455 | ||
| How to follow up and when to operate asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1? | Q87640196 | ||
| Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma | Q95583924 | ||
| Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. | Q35891227 | ||
| Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome | Q35922060 | ||
| The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. | Q36113256 | ||
| Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI. | Q36661451 | ||
| A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors | Q36661917 | ||
| Gastrinoma (duodenal and pancreatic). | Q36741116 | ||
| Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors | Q36843996 | ||
| Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE. | Q36957431 | ||
| Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas | Q36972533 | ||
| Localisation and staging of gastrin producing tumours using cross-sectional imaging modalities | Q36994217 | ||
| Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors | Q37056120 | ||
| Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective | Q37347947 | ||
| The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk | Q37607027 | ||
| Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy | Q37773478 | ||
| Tailored imaging of islet cell tumors of the pancreas amidst increasing options. | Q37894373 | ||
| Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis | Q37986605 | ||
| What extent of pancreatic resection do patients with MEN-1 require? | Q38026450 | ||
| Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. | Q38053116 | ||
| Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours | Q38098710 | ||
| Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis | Q38127505 | ||
| Zollinger-Ellison syndrome: recent advances and controversies | Q38150165 | ||
| Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life. | Q38157760 | ||
| Neuroendocrine tumours: the role of imaging for diagnosis and therapy | Q38169928 | ||
| Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. | Q38175794 | ||
| Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors | Q38181365 | ||
| The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. | Q38202029 | ||
| The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature | Q38241845 | ||
| Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. | Q38545523 | ||
| Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). | Q39994289 | ||
| Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome | Q40845787 | ||
| Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. | Q41012844 | ||
| Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes. | Q41201307 | ||
| Thymic and Bronchial Carcinoid Tumors in Multiple Endocrine Neoplasia Type 1: The Mayo Clinic Experience from 1977 to 2013. | Q41674195 | ||
| Surgery to cure the Zollinger-Ellison syndrome | Q41686955 | ||
| Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity | Q41719090 | ||
| Characterization of DNA damage-dependent cell cycle checkpoints in a menin-deficient model | Q42142535 | ||
| Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. | Q42443050 | ||
| Location, incidence, and malignant potential of duodenal gastrinomas | Q42468443 | ||
| The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors | Q42841246 | ||
| Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. | Q43227189 | ||
| Long-term follow-up of patients with multiple endocrine neoplasia type 1. | Q43712224 | ||
| Gastrinomas: localization by means of selective intraarterial injection of secretin | Q43908621 | ||
| Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors | Q44250446 | ||
| Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients | Q44301609 | ||
| Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. | Q45034203 | ||
| Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value | Q45196036 | ||
| Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. | Q46227275 | ||
| Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy | Q47424929 | ||
| Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients | Q47751377 | ||
| TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. | Q47867776 | ||
| Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome | Q48383339 | ||
| EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. | Q50599727 | ||
| Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. | Q50639178 | ||
| Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. | Q50671382 | ||
| Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. | Q50761477 | ||
| Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. | Q50794017 | ||
| Thymic carcinomas: clinicopathologic study of 37 cases from a single institution. | Q51280693 | ||
| Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. | Q51320250 | ||
| Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. | Q51356001 | ||
| Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. | Q51359463 | ||
| Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. | Q51420518 | ||
| Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? | Q51530644 | ||
| EUS Detection of Pancreatic Endocrine Tumors in Asymptomatic Patients with Type 1 Multiple Endocrine Neoplasia | Q52008601 | ||
| Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). | Q52992707 | ||
| Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? | Q53162886 | ||
| 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). | Q53283178 | ||
| Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). | Q53446846 | ||
| Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. | Q53560773 | ||
| Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. | Q53657069 | ||
| Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. | Q54233608 | ||
| Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. | Q54323177 | ||
| KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. | Q54474847 | ||
| Insulinoma | Q55952308 | ||
| 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | Q57757715 | ||
| Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1 | Q57819914 | ||
| Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’étude des Tumeurs Endocrines (GTE) cohort study | Q61647410 | ||
| Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study | Q61768229 | ||
| Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas | Q67955887 | ||
| P433 | issue | 1 | |
| P921 | main subject | multiple endocrine neoplasia | Q1553018 |
| multiple endocrine neoplasia type 1 | Q3347154 | ||
| P304 | page(s) | 53-66 | |
| P577 | publication date | 2016-01-18 | |
| P1433 | published in | International journal of endocrine oncology | Q27726155 |
| P1476 | title | Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies | |
| P478 | volume | 3 |
| Q38931272 | Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan |
| Q54945673 | Clinical implication of MEN1 mutation in surgically resected thymic carcinoid patients. |
| Q99557796 | Comparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome |
| Q50075239 | Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing |
| Q89420663 | Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies |
| Q52953312 | Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. |
| Q30491060 | Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. |
| Q39016753 | Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management |
| Q45360690 | Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms |
| Q64890693 | Recent Topics Around Multiple Endocrine Neoplasia Type 1. |
| Q54638848 | Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. |
| Q38956091 | Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies |
Search more.